Hoylu and Barton Malow Announce Latest Delivery at The Pennsylvania State University's University Park campus.
5.6.2017 08:30 | NASDAQ OMX
Barton Malow has deployed a two-projector Hoylu Huddlewall system at their $110M Chemical and Biomedical Engineering Building project at The Pennsylvania State University's University Park campus. The installation has quickly become the centerpiece of their top-of-the-line colocation modular complex, and routinely draws the interest of architects, engineers, consultants, and subcontractors involved with the project.
The installation is the latest showcase of Hoylu's commitment to the Construction Industry, providing the large-scale Hoylu Huddlewall display along with the Hoylu Inspiration Suite of software, which provides detailed collaboration and process planning as well as enabling industry-standard 3rd party applications with all the functionality that customers have come to know and love.
The Hoylu Huddlewall, which integrates a flexible, large format display with multiple forms of input including digital pen-based and digitally enabled analog paper, is primarily used for site logistics planning, Last Planner® activities, shop drawing review, and in multiple presentational settings. The flexibility and power of the system provides immediate ROI for companies in the process of creating innovative solutions in the Construction Industry.
"Our Assistant Superintendent hosts all of his weekly planning meetings on the wall, which has been an effective approach at getting complete buy-in from all attendees, who benefit from a clear, large format view of the presented information," said Patrick Laninger, Senior Project Engineer at Barton Malow Company "Our engineering team has utilized the wall to greatly improve the efficiency of our shop drawing review process, by juxtaposing contract drawings and shop drawings, and rapidly capturing the input of multiple individuals. This process has been far more efficient than our team's previously preferred method; passing a digital file around for individual review and performing the cumbersome task of reconciling commentary."
The Hoylu Huddlewall is also used for hosting informational training sessions for Penn State Engineering students interested in honing their project management skillsets, where its ability to deliver a stronger, more immersive experience for larger groups is quickly realized. Patrick Laninger explains; "Given the number of project team members who are Alumni of the Uuniversity, our location on campus, and our close relationship with Penn State's College of Engineering, we intend on consistently using the Huddlewall for these types of events over the course of the next two years. The logistical challenges associated with hosting a large number of people for technology-based demonstrations are nearly eliminated by the large format viewing experience that the Huddlewall provides."
"We are proud to work with a market leading company like Barton Malow, who is known for building incredibly innovative solutions," said Stein Revelsby, CEO of Hoylu. "There is a huge opportunity right now in the $712 Billion Construction industry to provide deep, immersive products that fundamentally transform the way the business works. It is an exciting time and we are extremely proud of this latest showcase of our products and technology."
Barton Malow Company
Founded in 1924, Barton Malow Company leads North America as one of the top performing contractors in markets that include education, energy, healthcare, industrial, manufacturing and sports facilities. Our core purpose is to Build with the American Spirit: People, Projects and Communities. We build innovative solutions through engaging cutting-edge virtual design and construction technologies, unique contracting methods and LEAN processes. The strength of our self-perform capabilities increases safety, quality, and productivity. Our long-term goal is to build innovative and trust- based solutions to double efficiency by our 100th anniversary in 2024.
Please visit us at www.bartonmalow.com and follow us on Facebook and Twitter, @bartonmalow
Hoylu delivers solutions for presentation, ideation and collaboration that focus on enhancing the user experience. The company's main area of interest is software for Creative Collaboration, combined with intuitive input and display technologies. This includes technologies for remote collaboration, Internet of Things and for connecting workspaces in different locations together, with the objective of simplifying work processes while improving productivity and creativity. For more information: www.hoylu.com or visit www.introduce.se/foretag/hoylu
Ticker symbol: Hoylu
Marketplace: Nasdaq First North Stockholm
Certified Adviser: Remium Nordic AB +46(0)84543200
For more information, please contact
Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: firstname.lastname@example.org
Karl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: email@example.com
The information was submitted for publication, through the agency of the contact person set out above, at (8:30) CEST on June 5, 2017
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Hoylu AB via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste nyheterna från NASDAQ OMX
Nasdaq Welcomes I-AM Capital Acquisition Company (Nasdaq: IAMXU) to The Nasdaq Stock Market17.8.2017 18:50 | Pressmeddelande
NEW YORK, Aug. 17, 2017 (GLOBE NEWSWIRE) -- I-AM Capital Acquisition Company (Nasdaq:IAMXU), a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, celebrated its initial public offering (IPO) on The Nasdaq Stock Market. I-AM Capital's founders, Chief Executive Officer F. Jacob Cherian and Chief Financial Officer Suhel Kanuga, have been focused on investing into India over the last decade, with the distinction of completing the first listed-SPAC investment in India. "Through our keen focus and unique accomplishments in India over the last decade, we have seen our investment thesis bear fruit: India's prominence and rise on the world stage, its distinction as being one of the fastest growing major economies of the world, and its strong vibrant consumer demographics. We believe these factors are aligning well now,
Tetraphase Pharmaceuticals Announces Submission and Validation of IV Eravacycline Marketing Authorization Application by European Medicines Agency17.8.2017 14:30 | Pressmeddelande
WATERTOWN, Mass., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical-stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant (MDR) infections, today announced that the Marketing Authorization Application (MAA) for IV eravacycline for the treatment of complicated intra-abdominal infections (cIAI) has been submitted and was validated by the European Medicines Agency (EMA). Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by multidrug-resistant (MDR) pathogens. The MAA filing is based on data from the phase 3 IGNITE1 clinical trial in which eravacycline was well tolerated and demonstrated statistical non-inferiority to ertapenem using the primary endpoint of clinical response at the test-of-cure (TOC) visit. "The MAA filing represents a significant milestone for Tetraphase as it is our
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules17.8.2017 13:00 | Pressmeddelande
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, prescription proton pump inhibitor (PPI), indicated for adults for the treatment of gastroesophageal reflux disease (GERD) and other gastrointestinal (GI) conditions RedHill expects to initiate the U.S. promotion of Esomeprazole Strontium DR Capsules 49.3 mg in the coming weeks Esomeprazole Strontium DR Capsules 49.3 mg will be the third commercial GI product to be promoted by RedHill in the U.S. RedHill's GI-focused sales force currently promotes two GI s
Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40 | Pressmeddelande
Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38 | Pressmeddelande
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical
CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00 | Pressmeddelande
CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go
I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum